Shire PLC (SHPG) Earns Buy Rating from Analysts at FBR & Co
Investment analysts at FBR & Co began coverage on shares of Shire PLC (NASDAQ:SHPG) in a research note issued on Thursday, Marketbeat reports. The brokerage set a “buy” rating and a $201.00 price target on the biopharmaceutical company’s stock. FBR & Co’s price objective would indicate a potential upside of 38.38% from the company’s current price.
A number of other research analysts also recently weighed in on SHPG. BidaskClub raised Shire PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Cantor Fitzgerald set a $222.00 price target on Shire PLC and gave the stock a “buy” rating in a research note on Saturday, July 1st. HSBC Holdings plc raised Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. ValuEngine raised Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $245.00 price objective on shares of Shire PLC in a report on Wednesday, July 12th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. Shire PLC currently has a consensus rating of “Hold” and a consensus price target of $219.25.
Shire PLC (NASDAQ:SHPG) traded down 1.74% during midday trading on Thursday, hitting $145.25. The stock had a trading volume of 1,078,686 shares. Shire PLC has a 52 week low of $139.36 and a 52 week high of $192.64. The company’s 50 day moving average price is $153.97 and its 200-day moving average price is $164.18. The stock has a market capitalization of $43.26 billion, a price-to-earnings ratio of 64.99 and a beta of 1.63.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities analysts anticipate that Shire PLC will post $14.92 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/22/shire-plc-shpg-earns-buy-rating-from-analysts-at-fbr-co.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Maverick Capital Ltd. grew its holdings in Shire PLC by 19.9% during the second quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock valued at $320,969,000 after purchasing an additional 322,610 shares during the period. Glenview Capital Management LLC grew its holdings in Shire PLC by 69.7% during the second quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock valued at $284,756,000 after purchasing an additional 707,500 shares during the period. Vanguard Group Inc. grew its holdings in Shire PLC by 0.9% during the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after purchasing an additional 13,665 shares during the period. Ameriprise Financial Inc. grew its holdings in Shire PLC by 14.7% during the second quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock valued at $249,577,000 after purchasing an additional 194,059 shares during the period. Finally, BlackRock Inc. grew its holdings in Shire PLC by 4,217.7% during the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after purchasing an additional 1,400,275 shares during the period. 19.24% of the stock is owned by institutional investors and hedge funds.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.